Prix Cizzle Biotechnology Holdings PLC (CIZZF)

Cizzle Biotechnology Holdings Plc is a holding company, which engages in detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. The firm is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. The company is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.